Please enable JavaScript to continue using this application.

Compare $FATE vs $LXEO | Chartloom

Compare

$FATE vs $LXEO

Fate Therapeutics Inc · Lexeo Therapeutics Inc

FATE

Fate Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Compare $FATE vs $LXEO

Comparing Fate Therapeutics Inc and Lexeo Therapeutics Inc

FATEFate Therapeutics Inc

LXEOLexeo Therapeutics Inc

FATEFate Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

54.34x

Rev growth (TTM)

-23.4%

YTD performance

120.2%

52W performance

44.4%

FCF yield

-41.6%

LXEOLexeo Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-66.4%

52W performance

-59.8%

FCF yield

-35.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FATE

LXEO

Detailed metrics comparison

FATE

Fate Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Market Cap

FATE$254M

LXEO$254M

Enterprise Value

FATE$234M

LXEO$161M

Price

FATE$2.18

LXEO$3.23

P/E Ratio

FATEN/A

LXEON/A

P/S Ratio

FATE39.15x

LXEO535.16x

EV/Sales

FATE35.98x

LXEO0.00x

EV/EBITDA

FATE0.00x

LXEO0.00x

P/B Ratio

FATE1.81x

LXEO1.23x

P/FCF Ratio

FATEN/A

LXEON/A

EV/FCF

FATE-2.21x

LXEO-1.82x

PEG Ratio

FATEN/A

LXEON/A

Forward P/E (NTM)

FATEN/A

LXEON/A

Forward P/S (NTM)

FATE54.34x

LXEON/A

Revenue (TTM)

FATE$6M

LXEO$0

Revenue Growth (YoY)

FATE-23.4%

LXEON/A

Forward Rev Growth

FATE-17.6%

LXEO466.0%

Gross Margin (TTM)

FATE0.0%

LXEO0.0%

Operating Margin (TTM)

FATE0.0%

LXEO0.0%

EBITDA Margin (TTM)

FATE-1873.4%

LXEO0.0%

Net Margin (TTM)

FATE-1941.1%

LXEO0.0%

FCF Margin (TTM)

FATE-1627.8%

LXEON/A

Net Income (TTM)

FATE$-126M

LXEO$-87M

FCF (TTM)

FATE$-106M

LXEO$-89M

EPS (TTM)

FATE-$1.05

LXEO-$1.02

ROE (TTM)

FATE-6508.0%

LXEO-4185.0%

ROA (TTM)

FATE-4173.0%

LXEO-3803.0%

ROIC (TTM)

FATE-6174.0%

LXEO-4169.0%

Cash

FATE$32M

LXEO$93M

Debt

FATE$12M

LXEO$584K

Net Cash/Debt

FATE$21M

LXEO$92M

Current Ratio (TTM)

FATE4.85x

LXEO13.89x

Quick Ratio (TTM)

FATE4.74x

LXEO13.49x

Debt/Equity (TTM)

FATE0.08x

LXEO0.00x

Debt/Assets (TTM)

FATE0.0%

LXEO0.0%

Interest Coverage (TTM)

FATEN/A

LXEON/A

Net Debt/EBITDA (TTM)

FATE0.00x

LXEO0.00x

Beta

FATE2.67

LXEO1.62

52W Performance

FATE44.4%

LXEO-59.8%

YTD Performance

FATE120.2%

LXEO-66.4%

% from 52W High

FATE-32.5%

LXEO-70.6%

% from 52W Low

FATE129.5%

LXEO8.4%

Asset Turnover (TTM)

FATE0.02x

LXEO0.00x

FCF Yield (TTM)

FATE-41.6%

LXEO-35.0%

Earnings Yield (TTM)

FATE-49.6%

LXEO-34.4%

Dividend Yield (TTM)

FATEN/A

LXEON/A

Rule of 40

FATE-1,651.1

LXEO0.0

EV/GP/RG

FATEN/A

LXEON/A

Ticker research

View FATE research View LXEO research

Metric	FATE Fate Therapeutics Inc	LXEO Lexeo Therapeutics Inc
Market & Valuation
Market Cap	$254M	$254M
Enterprise Value	$234M	$161M
Price	$2.18	$3.23
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	535.16x
EV/Sales	35.98x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	1.23x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-1.82x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.4%	N/A
Forward Rev Growth	-17.6%	466.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	0.0%
Net Margin (TTM)	-1941.1%	0.0%
FCF Margin (TTM)	-1627.8%	N/A
Net Income (TTM)	$-126M	$-87M
FCF (TTM)	$-106M	$-89M
EPS (TTM)	-$1.05	-$1.02
ROE (TTM)	-6508.0%	-4185.0%
ROA (TTM)	-4173.0%	-3803.0%
ROIC (TTM)	-6174.0%	-4169.0%
Financial Health
Cash	$32M	$93M
Debt	$12M	$584K
Net Cash/Debt	$21M	$92M
Current Ratio (TTM)	4.85x	13.89x
Quick Ratio (TTM)	4.74x	13.49x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	1.62
52W Performance	44.4%	-59.8%
YTD Performance	120.2%	-66.4%
% from 52W High	-32.5%	-70.6%
% from 52W Low	129.5%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.00x
FCF Yield (TTM)	-41.6%	-35.0%
Earnings Yield (TTM)	-49.6%	-34.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View LXEO research

Valuation

P/S Ratio

FATE

39.15x

LXEO

535.16x

EV/FCF

FATE

-2.21x

LXEO

-1.82x

Growth & revenue

Revenue Growth TTM

FATE

-23.4%

Forward Revenue Growth

LXEO

466.0%

FATE

-17.6%

Profitability & performance

Gross Margin

FATE

0.0%

LXEO

0.0%

ROE

LXEO

-4185.0%

FATE

-6508.0%

FCF Yield %

LXEO

-35.0%

FATE

-41.6%

52-Week Performance

FATE

44.4%

LXEO

-59.8%

Detailed metrics comparison

FATE

Fate Therapeutics Inc

LXEO

Lexeo Therapeutics Inc

Market Cap

FATE$254M

LXEO$254M

Enterprise Value

FATE$234M

LXEO$161M

Price

FATE$2.18

LXEO$3.23

P/E Ratio

FATEN/A

LXEON/A

P/S Ratio

FATE39.15x

LXEO535.16x

EV/Sales

FATE35.98x

LXEO0.00x

EV/EBITDA

FATE0.00x

LXEO0.00x

P/B Ratio

FATE1.81x

LXEO1.23x

P/FCF Ratio

FATEN/A

LXEON/A

EV/FCF

FATE-2.21x

LXEO-1.82x

PEG Ratio

FATEN/A

LXEON/A

Forward P/E (NTM)

FATEN/A

LXEON/A

Forward P/S (NTM)

FATE54.34x

LXEON/A

Revenue (TTM)

FATE$6M

LXEO$0

Revenue Growth (YoY)

FATE-23.4%

LXEON/A

Forward Rev Growth

FATE-17.6%

LXEO466.0%

Gross Margin (TTM)

FATE0.0%

LXEO0.0%

Operating Margin (TTM)

FATE0.0%

LXEO0.0%

EBITDA Margin (TTM)

FATE-1873.4%

LXEO0.0%

Net Margin (TTM)

FATE-1941.1%

LXEO0.0%

FCF Margin (TTM)

FATE-1627.8%

LXEON/A

Net Income (TTM)

FATE$-126M

LXEO$-87M

FCF (TTM)

FATE$-106M

LXEO$-89M

EPS (TTM)

FATE-$1.05

LXEO-$1.02

ROE (TTM)

FATE-6508.0%

LXEO-4185.0%

ROA (TTM)

FATE-4173.0%

LXEO-3803.0%

ROIC (TTM)

FATE-6174.0%

LXEO-4169.0%

Cash

FATE$32M

LXEO$93M

Debt

FATE$12M

LXEO$584K

Net Cash/Debt

FATE$21M

LXEO$92M

Current Ratio (TTM)

FATE4.85x

LXEO13.89x

Quick Ratio (TTM)

FATE4.74x

LXEO13.49x

Debt/Equity (TTM)

FATE0.08x

LXEO0.00x

Debt/Assets (TTM)

FATE0.0%

LXEO0.0%

Interest Coverage (TTM)

FATEN/A

LXEON/A

Net Debt/EBITDA (TTM)

FATE0.00x

LXEO0.00x

Beta

FATE2.67

LXEO1.62

52W Performance

FATE44.4%

LXEO-59.8%

YTD Performance

FATE120.2%

LXEO-66.4%

% from 52W High

FATE-32.5%

LXEO-70.6%

% from 52W Low

FATE129.5%

LXEO8.4%

Asset Turnover (TTM)

FATE0.02x

LXEO0.00x

FCF Yield (TTM)

FATE-41.6%

LXEO-35.0%

Earnings Yield (TTM)

FATE-49.6%

LXEO-34.4%

Dividend Yield (TTM)

FATEN/A

LXEON/A

Rule of 40

FATE-1,651.1

LXEO0.0

EV/GP/RG

FATEN/A

LXEON/A

Ticker research

View FATE research View LXEO research

Metric	FATE Fate Therapeutics Inc	LXEO Lexeo Therapeutics Inc
Market & Valuation
Market Cap	$254M	$254M
Enterprise Value	$234M	$161M
Price	$2.18	$3.23
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	535.16x
EV/Sales	35.98x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	1.23x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-1.82x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	-23.4%	N/A
Forward Rev Growth	-17.6%	466.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	0.0%
Net Margin (TTM)	-1941.1%	0.0%
FCF Margin (TTM)	-1627.8%	N/A
Net Income (TTM)	$-126M	$-87M
FCF (TTM)	$-106M	$-89M
EPS (TTM)	-$1.05	-$1.02
ROE (TTM)	-6508.0%	-4185.0%
ROA (TTM)	-4173.0%	-3803.0%
ROIC (TTM)	-6174.0%	-4169.0%
Financial Health
Cash	$32M	$93M
Debt	$12M	$584K
Net Cash/Debt	$21M	$92M
Current Ratio (TTM)	4.85x	13.89x
Quick Ratio (TTM)	4.74x	13.49x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	1.62
52W Performance	44.4%	-59.8%
YTD Performance	120.2%	-66.4%
% from 52W High	-32.5%	-70.6%
% from 52W Low	129.5%	8.4%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.00x
FCF Yield (TTM)	-41.6%	-35.0%
Earnings Yield (TTM)	-49.6%	-34.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View LXEO research